STROBE Statement - Checklist of items that should be included in reports of cohort studies

|  | $\begin{gathered} \text { Item } \\ \text { No } \end{gathered}$ | Recommendation |
| :---: | :---: | :---: |
| Title and abstract | 1 | (a) study's design with a commonly used term in the title or the abstract Inserted |
|  |  | (b) the abstract an informative and balanced summary of what was done and what was found Completed |
| Introduction |  |  |
| Background/rationale | 2 | scientific background and rationale for the investigation being reported |
| Objectives | 3 | specific objectives, including any prespecified hypotheses STATED |
| Methods |  |  |
| Study design | 4 | key elements of study design early in the paper PRESENTED |
| Setting | 5 | the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection DESCRIBED |
| Participants | 6 | (a) the eligibility criteria, and the sources and methods of selection of participants. GIVEN |
|  |  | (b) For matched studies, give matching criteria and number of exposed and unexposed N/A |
| Variables | 7 | all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable N/a |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Data sources explained |
| Bias | 9 | Describe any efforts to address potential sources of bias USE OF RASCH MODELLING FOP ITEM RELIABILITY UNDERTAKEN |
| Study size | 10 | Explain how the study size was arrived at see item 6 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why BIVARIATE AND MULTIVARIATE DATA ANLAYSIS WAS DESCRIBED |
| Statistical methods | 12 |  |
|  |  | (b) Describe any methods used to examine subgroups and interactions |

(c) Explain how missing data were addressed multiple imputation method used...
(d) If applicable, explain how loss to follow-up was addressed N/A
(e) Describe any sensitivity analyses N/A

| Results | $13^{*}$ | (a) Report numbers of individuals at each stage of study- <br> eg numbers potentially eligible, examined for eligibility, <br> confirmed eligible, included in the study, completing <br> follow-up, and analysed N/A |
| :--- | :--- | :--- |
|  | (b) Give reasons for non-participation at each stage N/A |  |
|  | (c) Consider use of a flow diagram N/A |  |
| Descriptive data | $14^{*}$ | (a) Give characteristics of study participants (eg <br> demographic, clinical, social) and information on exposures <br> and potential confounders GIVEN |
| (b) Indicate number of participants with missing data for <br> each variable of interest see item 12c |  |  |
| (c) Summarise follow-up time (eg, average and total |  |  |
| amount) N/A |  |  |


| Generalisability | 21 | Discuss the generalisability (external validity) of the study <br> results limited only to the results of this one group of <br> midwives |
| :--- | :--- | :--- |
| Other information | 22 | Give the source of funding and the role of the funders for <br> the present study and, if applicable, for the original study on <br> which the present article is based /NIL |
| Funding |  |  |

© 2020 Blackman I. et al.

